Role of HDL in Those with Diabetes
- 21 June 2014
- journal article
- review article
- Published by Springer Nature in Current Cardiology Reports
- Vol. 16 (9) , 1-14
Abstract
Low levels of high-density lipoprotein cholesterol (HDL-C) have been associated with an increased risk of coronary heart disease in prospective population studies and clinical trials of high-risk patients treated with a low to moderate intensity statin. As a result, therapeutic targets were developed to increase concentrations of HDL-C. Subsequently, clinical trials of high-intensity statins have not supported this previously well-established association. In trials of high-intensity statin therapy, low HDL particle concentration (HDL-P) has been associated with an increased risk of future cardiovascular events. Therefore, strategies that increase HDL-C without expanding the pool of HDL-P with its rich proteome/lipidome do not seem to be an effective strategy. In this review, we discuss potential mechanisms of action for the anti-atherogenic effect of HDL and the impact of current and emerging therapies on the functional capacity of HDL-P. Finally, we discuss emerging therapies that increase the concentration and functional properties of HDL.Keywords
This publication has 120 references indexed in Scilit:
- RETRACTED: Primary Prevention of Cardiovascular Disease with a Mediterranean DietNew England Journal of Medicine, 2013
- Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation studyThe Lancet, 2012
- High-Density Lipoprotein Cholesterol and Particle Concentrations, Carotid Atherosclerosis, and Coronary EventsJACC, 2012
- Vascular effects and safety of dalcetrapib in patients with or at risk of coronary heart disease: the dal-VESSEL randomized clinical trialEuropean Heart Journal, 2012
- Cholesterol Efflux Capacity, High-Density Lipoprotein Function, and AtherosclerosisNew England Journal of Medicine, 2011
- Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysisThe Lancet, 2010
- Effects of Combination Lipid Therapy in Type 2 Diabetes MellitusNew England Journal of Medicine, 2010
- Cholesteryl ester transfer protein: at the heart of the action of lipid-modulating therapy with statins, fibrates, niacin, and cholesteryl ester transfer protein inhibitorsEuropean Heart Journal, 2009
- Proteomic Analysis of Defined HDL Subpopulations Reveals Particle-Specific Protein ClustersArteriosclerosis, Thrombosis, and Vascular Biology, 2009
- Lipoprotein particles, insulin, adiponectin, C-reactive protein and risk of coronary heart disease among men with metabolic syndromeAtherosclerosis, 2007